Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

HCV infection in HIV patients does not increase risk of death or developing AIDS

Infection with hepatitis C virus (HCV) does not appear to increase the risk of death or developing AIDS for HIV patients, nor decrease the response to effective antiretroviral treatment, according to an article to be published in the next issue of the Journal of the American Medical Association.

News image

fiogf49gjkf04

Mark S. Sulkowski, of Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, and colleagues conducted a study to assess the effect of HCV infection on clinical and immunologic progression of HIV infection and immunologic response to highly active antiretroviral therapy (HAART).

Co-author Richard E. Chaisson, presented the findings of the research at a JAMA media briefing at the International AIDS Conference in Barcelona, Spain.

According to background information in the article, there are conflicting reports regarding the effect of HCV on the progression of HIV disease.

HIV infection appears to increase the likelihood that HCV infection will become chronic, and, in most studies, increase the risk of progressive HCV-related liver disease.

Due to shared routes of transmission such as by contaminated needles, an estimated 15-30% of HIV-infected persons are coinfected with HCV in the United States and Europe.

The study included 1955 patients enrolled between 1995 and 2001 at the Johns Hopkins Hospital HIV Clinic.

The patients had at least one return visit to the clinic and were free of AIDS at enrolment.

45% of the patients had HCV and HIV coinfection.
Journal of the American Medical Association

It was found that 45% of patients had HCV infection. Median length of follow-up was 2.2 years for HCV-infected and 2.0 years for HCV-uninfected patients.

The authors found, "After adjustment for the administration of HAART and its effectiveness, we did not detect an increased risk of development of AIDS-defining illness, death, or CD4 cell count decline to below 200/µl among HCV-infected compared with HCV-uninfected patients.

"In addition, among patients prescribed HAART, we found no evidence that HCV infection alters the virological or immunologic response to potent antiretroviral therapy."

Comparing HCV-infected patients with HCV-uninfected patients, there were no significant differences for acquiring an AIDS-defining illness (26% vs 24%, respectively) or risk of death (18% vs 16%).

Among patients treated with HAART, HCV status was not associated with HIV suppression or CD4 cell response. However, fewer HCV-infected patients received HAART (54%) compared with HCV-uninfected patients (67%).

"Further research is still needed to understand the effect of HCV infection on HIV disease and immune reconstitution in response to HAART.

"However, these findings emphasize the importance of the consideration of effective antiretroviral therapy for HCV-infected and HCV-uninfected persons at immediate risk for the development of AIDS," the authors conclude.

In an accompanying editorial, Stephen J. Rossi and colleagues of the Department of Veterans Affairs Medical Center, and the University of California, San Francisco, comment on the study.

"How should these studies guide clinicians in the management of patients with HCV/HIV coinfection?

"It is likely that many patients with HIV and HCV coinfection will be unable to be treated effectively with current HCV regimens," the authors continue.

"The HCV therapy should be initiated in patients who are expected to tolerate treatment, either before HIV therapy if the latter can be delayed, or during HIV therapy, to delay progression of liver disease.

"Optimal HCV/HIV management will require educating clinicians about the potential for drug interactions between HCV and HIV therapies, continued education of patients about the importance of adherence to prescribed regimens, and for both, education about the importance of alcohol cessation," the authors write.

"Certainly, the patient with coinfection highlights the importance of developing improved HCV regimens that avoid the toxicities of current interferon-based therapies."

JAMA 2002; 288:199-206, 241-3
08 July 2002

Go to top of page Email this page Email this page to a colleague

 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 11 May 2018 
Depressive symptoms in IBD youth
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
PPI use and cognitive decline
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Fecal incontinence and quality of life in IBD
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 24 April 2018 
PPI and risk of stroke
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Worldwide H.pylori prevalence
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us